- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald | 2 | Investing.com | ||
| ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 16.01. | Cantor Fitzgerald bestätigt "Overweight"-Rating für ArriVent | - | Investing.com Deutsch | ||
| 06.01. | ArriVent BioPharma: Oppenheimer bestätigt "Outperform"-Rating und Kursziel von 44 US-Dollar | 3 | Investing.com Deutsch | ||
| 06.01. | Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock | 1 | Investing.com | ||
| 22.12.25 | Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating | 3 | Investing.com | ||
| 22.12.25 | ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug | 3 | Investing.com | ||
| 22.12.25 | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | 164 | GlobeNewswire (Europe) | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| 10.12.25 | ArriVent BioPharma: BTIG startet mit Kaufempfehlung wegen Onkologie-Potenzial | 2 | Investing.com Deutsch | ||
| 10.12.25 | ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential | 1 | Investing.com | ||
| 25.11.25 | ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug | 3 | Investing.com | ||
| 10.11.25 | ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street | 5 | Investing.com | ||
| 10.11.25 | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | ArriVent BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.09.25 | ArriVent BioPharma appoints Brent Rice as chief commercial officer | 2 | Investing.com | ||
| 22.09.25 | ArriVent BioPharma beruft Brent Rice zum Chief Commercial Officer | 1 | Investing.com Deutsch | ||
| 22.09.25 | ArriVent BioPharma, Inc.: ArriVent Appoints Brent S. Rice as Chief Commercial Officer | 303 | GlobeNewswire (Europe) | NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of... ► Artikel lesen | |
| 09.09.25 | ArriVent reports 16-month PFS for lung cancer drug firmonertinib | 1 | Investing.com | ||
| 09.09.25 | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08.25 | ArriVent BioPharma GAAP EPS of -$0.90 misses by $0.20 | 1 | Seeking Alpha | ||
| 11.08.25 | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | 929 | GlobeNewswire (Europe) | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 15,400 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,650 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 69,98 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| IMMUNOVANT | 26,450 | 0,00 % | Immunovant Inc.: Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | ||
| ALUMIS | 26,840 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 11,160 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,880 | 0,00 % | Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? | ||
| STRUCTURE THERAPEUTICS | 87,15 | 0,00 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| IMMUNOME | 25,070 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 10,310 | 0,00 % | Erasca, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 72,56 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,68 | +1,54 % | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | ||
| RECURSION PHARMACEUTICALS | 4,320 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,730 | 0,00 % | Arcutis, Kowa part ways on US marketing partnership for Zoryve | ||
| MINERALYS THERAPEUTICS | 32,090 | -0,77 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
Das Unternehmen ARRIVENT BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 22,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARRIVENT BIOPHARMA INC finden Sie auf Wallstreet Online.